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Brief Statement of Key Findings:  Besides serving as a signal for phagocytic recognition 
and removal of apoptotic cells, cell surface PS can also function as an adhesion ligand.  PS-dependent 
erythrocyte adhesion to endothelium and sub-endothelial matrix components is mediated in part via TSP.  
We demonstrate that PS-positive erythrocytes bind to TSP via its heparin-binding domain and that both 
heparin and enoxaparin, at clinically relevant concentrations, block this interaction.  Our results taken 
together with previously documented heparin inhibitory effects on P-selectin- and soluble-TSP-mediated 
sickle erythrocyte-endothelial adhesion suggest that heparin and its low-molecular-weight derivatives may 
prove beneficial as anti-adhesive therapeutics targeting various pathways in the erythrocyte adhesion-
cascade. 
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ABSTRACT 
 
Phosphatidylserine (PS)-dependent erythrocyte adhesion to endothelium and 
sub-endothelial matrix components is mediated in part via thrombospondin (TSP).  
While TSP exhibits multiple cell-binding domains, the PS-binding site on TSP is 
unknown.  Since a cell-binding domain for anionic heparin is located at the amino-
terminus, we hypothesized that PS-positive red cells (PS+ve-RBCs) bind to this domain.  
We demonstrate that both heparin and its low-molecular-weight derivative enoxaparin 
(0.5-50u/ml) inhibited PS+ve-RBC adhesion to immobilized TSP in a concentration-
dependent manner (21-77% inhibition, P<0.05).  Pre-incubation of immobilized TSP with 
an antibody against the heparin-binding domain blocked PS+ve-RBC adhesion to TSP.  
Antibodies that recognize the collagen- and the carboxy-terminal CD47-binding domain 
on TSP had no effect on this process.  While pre-incubation of PS+ve-RBCs with TSP-
peptides from the heparin-binding domain containing the specific heparin-binding motif 
KKTRG inhibited PS+ve-erythrocyte adhesion to matrix TSP (P<0.001), these peptides in 
the immobilized form supported PS-mediated erythrocyte adhesion.  A TSP-peptide 
lacking the binding-motif neither inhibited nor supported PS+ve-RBC adhesion.  
Additional experiments show that soluble-TSP also interacted with PS+ve-RBCs via its 
heparin-binding domain.  Our results demonstrate that PS-positive erythrocytes bind to 
both immobilized and soluble TSP via its heparin-binding domain and that both heparin 
and enoxaparin, at clinically relevant concentrations, block this interaction.  Other 
studies have shown that heparin inhibited P-selectin- and soluble-TSP-mediated sickle 
erythrocyte adhesion to endothelial cells.  Our results taken together with the previously 
documented findings provide a rational basis for clinical use of heparin or its low-
molecular-weight derivatives as therapeutic agents in treating vaso-occlusive pain in 
patients with sickle cell disease.   
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ABBREVIATIONS:   BCAM/LU = basal cell adhesion molecule/Lutheran protein; 
CSA = chondroitin sulfate A; FITC = fluorescein isothiocyanate; GAGs = 
glycosaminoglycans; HDS = High molecular weight dextran sulfate; IAP = integrin-
associated protein; PS = phosphatidylserine; SCD = sickle cell disease; TC = Tri-Color; 
TSP = thrombospondin; VLA4 = very late activation antigen-4   
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INTRODUCTION 
 Phosphatidylserine (PS), an anionic phospholipid present exclusively in the inner 
leaflet of the plasma membrane of normal cells, is externalized following cell activation 
by both physiologic and pathologic stimuli.1,2  It has been well recognized that PS 
exposure on the cell surface serves as a signal for phagocytic recognition and removal 
of apoptotic cells.3  It can also function as an adhesion ligand mediating cell-cell 
interaction.  PS-mediated erythrocyte adhesion to endothelial cells and/or sub-
endothelial matrix components has been documented in patients with many hemolytic 
anemias including sickle cell disease (SCD),4 malaria,5 and uremia6 with documented 
positive correlation in SCD between the levels of percent PS-positivity and red cell-
endothelial adhesion.4  Abnormal erythrocyte adhesion appears to play an important 
role in vascular complications seen not only in patients with SCD,7 but also in malaria5 
and uremia.6  PS-dependent erythrocyte adhesion appears to be mediated in part via 
thrombospondin (TSP),8 a multifunctional and a matricellular glycoprotein.9-13  TSP is 
synthesized and released by a variety of mammalian cells including endothelial cells, 
and is incorporated into their matrix, becoming exposed following endothelial injury or 
cell retraction induced by agonists such as thrombin.14-17  As shown in Figure-1, while 
TSP can interact with a variety of cells via specific cell-binding domains on the 
molecule,9-13 the binding site for the anionic PS on the TSP molecule has not been 
identified to date.  In this study, we demonstrate that PS-positive erythrocytes bind to 
both soluble and immobilized TSP via its heparin-binding domain.   
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MATERIALS and METHODS 
Materials: Purified thrombospondin-1 from human platelets (referred to as TSP 
in this manuscript), annexin-V-pure (product A9460) and unfractionated heparin (from 
porcine intestine) were purchased from Sigma Chemical (St Louis, MO).  Enoxaparin, a 
low molecular weight heparin derivative (Aventis Pharmaceuticals, Sanofi-Aventis, 
Bridgewater, NJ) was obtained through Jefferson University Hospital Pharmacy.  High 
molecular weight dextran sulfate or HDS (ICN Biochemicals, Cleveland, OH), 
chondroitin sulfate A or CSA (from bovine trachea), calcium ionophore A23187 
(Calbiochem, La Jolla, CA) and fluorescein isothiocyanate (FITC)-labeled annexin-V (R & 
D Systems, Minneapolis, MN) were also obtained. Mouse monoclonal antibodies 
against human thrombospondin: TSP Ab-9 (isotype IgG1, clone MBC200.1), TSP Ab-4 
(isotype IgG1, clone A6.1), and TSP Ab-3 (isotype IgG1, clone C6.7) were procured from 
Lab Vision Corporation (Fremont, CA).  These anti-TSP antibodies have previously 
been demonstrated to specifically recognize the N-terminal heparin-, the collagen-, and 
the C-terminal CD47-binding domain on TSP, respectively,18-21 as depicted in Figure-1.  
Both TSP-Ab9 and TSP-Ab3 functionally block red cell, platelet and melanoma cell 
adhesion to TSP.18-21  Antibodies against human CD36 (clone FA6.152), CD49d (α-chain 
of the VLA4 or very late activation antigen-4, clone HP2.1), CD47 (integrin-associated 
protein or IAP, clone BRIC126), CD239 (basal cell adhesion molecule/Lutheran protein or 
BCAM/LU, clone BRIC221), isotype-matched negative control antibody (clone 
679.1Mc7), and FITC- and Tri-Color (TC)-labeled goat anti-mouse IgG were obtained 
from Immunotech (Beckman Coulter, Miami, FL), Serotec (Oxford, UK), or Caltag 
Laboratories (Burlingame, CA).  Three TSP peptides from the amino-terminal heparin-
binding domain of TSP containing the amino acid sequences KKTRGTLLALERKDHS 
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(the heparin-binding motif is italicized in bold, residues 80-95, TSP peptide-1), 
VDAVRTEKGFLLLASRQMKKTRGT (residues 61-85, peptide-2), and a TSP peptide 
without the binding motif TLLALERKDHS (residues 85-95, peptide-3) were synthesized 
through Sigma Genosys (Woodlands, TX).  The TSP peptides -1 and -2 (positive 
peptides) support adhesion of a wide variety of cells including murine 3T3 fibroblasts, 
several human breast carcinoma cells, human Bowes melanoma cells, human 
osteoblastic cells and Chinese hamster ovary cells,22,23 and inhibit binding of Chinese 
hamster ovary cells to immobilized N-terminal domain of TSP.23  The negative TSP 
peptide (peptide-3) neither supported cell adhesion nor inhibited cell binding to 
immobilized N-terminal domain of TSP.22,23  
Preparation of PS-positive Red Cells: For the majority of experiments, PS 
positive HbAA erythrocytes were generated artificially from fresh adult control blood. 
PS-positive red cells were prepared by treating control erythrocytes with A23187,24,25 
which routinely yielded a red cell preparation with PS positivity in the range of 60 to 
75%.  The ionophore-activated erythrocytes were suspended to a final concentration of 
2x108 cells/ml in adherence buffer (10mM HEPES in Hanks balanced salt solution 
[buffer-A], pH 7.4 containing 1.3mM CaCl2, 0.7mM MgCl2 and 0.5% BSA), unless 
otherwise indicated.  Untreated washed control erythrocytes (2x108 cells/ml in 
adherence buffer) served as the PS-negative control.  Ionophore-treated PS-positive 
red cells were diluted with untreated PS-negative erythrocytes from the same donor to 
obtain PS-positivity in the range of 0.5 to 17.5%. Cell surface PS and other adhesion 
markers on test erythrocytes were analyzed by flow cytometry.26,27  Select experiments 
also were performed using erythrocytes obtained from 12 SCD patients with HbSS 
genotype, without subjecting these cells to any in vitro treatment.  Blood samples were 
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collected from patients with steady state disease (ages 6 to 15 years) during their 
routine out-patient clinic visit.  This study was reviewed and approved by the 
Institutional Review Committee for the protection of human subjects at Thomas 
Jefferson University and at St Christopher’s Hospital for Children, Drexel University.  In 
accordance with the Declaration of Helsinki, blood samples were obtained following 
informed consent.  For minors, patient assent where appropriate was obtained in 
addition to parental permission.   
Flow Adhesion Assay:  For flow adhesion, matrices were prepared by coating pre-
washed glass slides (25mm X 75mm) with desired concentrations of TSP (25 to 200 ng 
protein per cm2 in bicarbonate buffer, 0.5M, pH 9.6), air-dried, rinsed with the 
adherence buffer, and used.  Erythrocyte adherence to immobilized TSP was evaluated 
using a parallel plate flow chamber as described by Hillery and coworkers.28  A shear 
rate of 1 dyne/cm2, a force equivalent to that in the post-capillary venule was employed, 
and adherence buffer was used in all steps of the assay.  The matrix was 
preconditioned with the wash buffer under flow for 5-minutes, erythrocytes were then 
allowed to flow over the matrix for 3-minutes followed by a wash-off of non-adherent 
cells for 10-minutes. To enumerate adherent erythrocytes, each matrix was divided 
vertically into five equal segments, the central area of each segment photographed, and 
the images analyzed using Image-Pro Software (Media Cybernetics, Silver Spring, MD), 
with each data point representing the mean of these five evaluations. Results are 
presented as the number of adherent cells/mm2.  To evaluate the effects on adhesion of 
heparin, enoxaparin, other glycosaminoglycans or GAGs including CSA and HDS, and 
TSP-peptides, erythrocytes were pre-incubated for 30-minutes at 37˚C in the presence 
or absence of the desired agent prior to adhesion.  To evaluate the effects of antibodies 
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and sulfatides, immobilized TSP matrix was pre-incubated with the desired test reagent 
at room temperature for 30-minutes by flooding the matrix with the desired antibody at 
10 µg/ml or sulfatide at 200µg/ml. Matrices were washed and adhesive potential 
assessed.  To verify the involvement of PS in adhesion, erythrocytes were pre-
incubated at 37˚C in the presence of the indicated concentrations of annexin-V for 30-
minutes to cover surface PS and then tested for their adhesive potential to immobilized 
TSP.  Red cell surface PS was evaluated by flow cytometry using annexin-V-FITC. 
Binding Studies with Soluble Thrombospondin:  Erythrocytes (1x108 cells/ml 
containing 12% PS-positive verses PS-negative cells) were pre-incubated at 37˚C in the 
presence of the indicated concentrations of soluble TSP for 60-minutes, and then 
evaluated for erythrocyte-bound TSP using indirect immunostaining, and employing the 
monoclonal antibodies TSP-Ab9 and TSP-Ab4.  In brief, erythrocytes that had been pre-
incubated with soluble TSP were washed twice with buffer-A containing 1% bovine 
serum albumin, 1.3mM CaCl2 and 0.7mM MgCl2.  Washed red cells (1x106 cells) were 
incubated with 2µg primary antibody (TSP-Ab9, TSP-Ab4, or isotype-matched negative 
control) for 30-minutes at room temperature.  After two washes, the antibody-labeled 
erythrocytes were incubated with 1µg TC-labeled goat anti-mouse IgG for 30-minutes at 
room temperature, washed, and analyzed by flow cytometry.  
Statistical Analysis: Statistical evaluation was performed using Sigmastat 
Statistical Package (Systat, Richmond, CA).  All results are presented as mean±SD.  
Comparison between controls and paired treatment groups (effects of GAGs and TSP 
peptides on red cell adhesion to TSP, erythrocyte adhesion to TSP peptides, and  
adhesion marker levels on control verses ionophore-activated erythrocytes) was 
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performed using the paired student t-test or the Mann-Whitney rank sum test on the 
medians, if the data showed non-normal distribution.  Unpaired student t-test or the 
Mann-Whitney rank sum test was employed to compare the differences in levels of 
adhesion markers between high PS and low PS groups.  Multiple group comparison 
(dose response effects with heparin and enoxaparin, and effects of TSP antibodies and 
divalent cations on PS-TSP adhesion) was performed using either one-way ANOVA (for 
data with normal distribution) or the Kruskal-Wallis test (for data with non-normal 
distribution).  If the P-value for this overall comparison was significant at P<0.05, then 
group-wise comparison was performed using the Dunnett’s or the Dunn’s test.   
 
RESULTS 
Binding of PS-positive Erythrocyte to Immobilized Thrombospondin:  Initial 
binding experiments (n=4) were performed in adherence buffer using erythrocyte 
preparations containing 0.5 to 17.5% PS-positive cells and immobilized TSP matrices 
containing 25 to 200 ng protein per cm2.  Binding of PS-positive erythrocytes to matrix 
TSP increased almost linearly up to 12% (Figure-2A).  Similarly, red cell binding 
increased linearly between 25 and 100 ng matrix TSP with a marginal increase noted 
between 100 and 200 ng protein (Figure-2B).  In all further studies to be described we 
have employed a matrix concentration of 50 ng/cm2 and a red cell PS-positivity of 12%, 
since this experimental condition produced ~25-fold increase in erythrocyte binding 
compared to the control matrix without TSP permitting us to evaluate both inhibitory and 
stimulatory responses within the same experiment without changing experimental 
parameters between treatments. Requirement of divalent cations including Ca2+ and 
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Mg2+ in adhesion was next evaluated.  While neither Ca2+ nor Mg2+ alone significantly 
modulated red cell interaction with TSP, presence of both cations in the binding buffer 
increased PS-mediated erythrocyte adhesion by 12-fold (p<0.01).  All binding assays 
described in this study were, therefore, performed in medium containing Ca2+ (1.3mM) 
and Mg2+ (0.7mM).  In the presence of both Ca2+ and Mg2+, 644 ± 123 red cells adhered 
per mm2 when PS-positive cells were used in adhesion, in contrast to 20 ± 8 cells with 
PS-negative control erythrocytes.  PS specificity in adhesion was tested using the 
calcium-dependent PS-specific binding protein, annexin-V.29  As shown in Figure-3A, 
pre-treatment of red cell PS with annexin-V blocked PS-mediated cell binding to TSP 
matrix and reduced surface PS in parallel, confirming PS-TSP adhesion specificity.  
Effects of Heparin, Enoxaparin, HDS, CSA and Sulfatide on PS-mediated 
Erythrocyte Binding to Immobilized Thrombospondin:  To test the hypothesis that 
PS-positive erythrocytes interacted with the N-terminal domain of TSP which supports 
binding of anionic polysaccharides including heparin, we evaluated the effects of 
heparin (0.1 to 50 units/ml) on PS-positive red cell adhesion to immobilized TSP.  We 
demonstrate that heparin blocked erythrocyte binding to immobilized TSP in a 
concentration-dependent manner with significant inhibition of 44 to 77% noted at 0.5 to 
50 units/ml heparin (Figure-3B).  We next tested whether other anionic polysaccharides 
including HDS and CSA modulated PS-positive erythrocyte binding to TSP.  Results 
presented in Figure-3C demonstrate that both HDS and CSA inhibited PS-mediated cell 
binding to TSP with the magnitude of the inhibitory effects comparable to that of heparin 
(~70% inhibition).  These findings demonstrate that a charge-based interaction plays a 
role in erythrocyte binding to TSP.  Enoxaparin, a low molecular weight heparin 
derivative, and an anticoagulant and antithrombotic therapeutic agent, also inhibited PS-
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mediated red cell adhesion to immobilized TSP in a concentration-dependent manner 
with significant inhibitory effects of 21 to 52% noted at concentrations between 0.5 and 
50 units/ml (Figure-3B).  The inhibitory effects noted with enoxaparin were lower when 
compared to that seen with un-fractionated heparin.  In contrast to GAGs, bovine brain 
sulfatide had no effect on PS-mediated erythrocyte adhesion to immobilized TSP 
(Figure-3C).      
 Effects of anti-Thrombospondin Antibodies on PS-mediated Erythrocyte 
Binding to Immobilized Thrombospondin: To test whether the heparin-binding 
domain on TSP was involved in PS-mediated red cell binding to TSP, we evaluated the 
effects of three specific monoclonal anti-TSP antibodies: TSP-Ab3, TSP-Ab4 and TSP-
Ab9, which recognize the C-terminal CD47-, the collagen-, and the N-terminal heparin- 
binding domain on TSP, respectively (Figure-1).  As depicted in Figure-4A, pre-
treatment of TSP matrix with TSP-Ab9 (antibody recognizing the heparin-binding 
domain) showed a significant reduction in erythrocyte binding compared to either the 
vehicle control or the IgG control (approximately 70 to 80% inhibition, P<0.05).  TSP-
Ab3, and TSP-Ab4, which recognize the CD47- and the collagen-binding domain on 
TSP, had no effect.  To test whether PS-positive erythrocytes from a pathologic milieu 
interact with immobilized TSP in a manner similar to artificially generated PS-positive 
cells, in binding experiments, erythrocytes from SCD patients with HbSS disease 
containing various levels of PS positivity ranging from 0.6% to 8.1% were evaluated.  
These erythrocytes were divided into two experimental groups including low versus high 
PS-positive sickle erythrocytes (1.1±0.5% versus 6.6±1.7% PS positivity, P<0.001, 
Table-1) as we have done in our previous studies.4,25  As depicted in Figure-4B, while 
the anti-TSP antibody Ab9 had no significant effect on adhesion of low percent PS 
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positive HbSS erythrocytes to immobilized TSP, a significant inhibition in adhesion to 
TSP of HbSS erythrocytes containing high percent PS positive cells was noted (38 ± 8% 
inhibition, P<0.05).  
Effects of Thrombospondin Peptides on PS-mediated Erythrocyte Binding 
to Immobilized Thrombospondin:  To confirm that PS-positive red cells bind to 
heparin-binding domain on TSP, in binding assays we evaluated the effects of three 
previously characterized TSP peptides: two peptides containing the specific heparin 
binding motif KKTRG (positive peptides, peptides -1 and -2), and a third peptide lacking 
the binding motif (negative peptide, peptide-3).22,23  In preliminary experiments TSP 
peptide-1 blocked PS-mediated erythrocyte adhesion to immobilized TSP in a 
concentration-dependent manner with 30, 53, and 54% inhibition noted at 25, 50, and 
100 µM, respectively.  Our subsequent experiments were therefore performed using 
TSP peptides at 50 µM, since maximal inhibitory effects on adhesion were noted at this 
peptide concentration.  In paired experiments (n=7), pretreatment of PS-positive red 
cells with TSP peptides -1 and -2 inhibited cell binding to immobilized TSP by 53% and 
45%, respectively (P<0.001, Figure-5A).  The negative peptide had no effect on this 
process (P>0.75).  Inhibition of erythrocyte adhesion to immobilized TSP by TSP 
peptides indicated that these peptides interact directly with PS-positive red cells and 
suggested that the TSP peptides might support cell adhesion.  We next evaluated 
whether red cells bind to immobilized TSP peptides and demonstrate that while no 
erythrocytes adhered to immobilized negative peptide (peptide-3), both positive TSP  
peptides (peptides-1 and -2) supported PS-mediated red cell binding (Figure-5B).  
These results taken together demonstrate that the heparin-binding domain on TSP 
supports PS-mediated erythrocyte binding to TSP.     
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 Soluble Thrombospondin Binds to PS-positive Erythrocytes:  Since protein 
conformation of immobilized TSP may be different from that of soluble TSP, we 
investigated whether PS-positive erythrocytes bind to the same cell binding domain(s) 
on both soluble and immobilized TSP.  Erythrocytes were incubated in the presence of 
increasing concentrations of soluble TSP (1 to 10 µg/ml), washed and then assessed for 
TSP positivity using the previously tested anti-TSP antibodies. As depicted in Figure-6A, 
while a minimal number of TSP-positive red cells were detected at all TSP 
concentrations tested using TSP-Ab9, an antibody that recognizes the heparin-binding 
domain on TSP (hatched bars), a concentration-dependent increase in TSP-positive red 
cells was observed with TSP-Ab4, an antibody that recognizes the collagen-binding 
domain (cross-hatched bars).  No TSP-positive erythrocytes were detected when PS-
negative red cells were incubated with soluble TSP (solid bars).  Histogram profiles of 
TSP-positive red cells from a representative experiment are shown in Figure-6B 
demonstrating that TSP positivity on the red cell could be detected only with TSP-Ab4 
(A2).  TSP-positive red cells were almost undetectable when TSP-Ab9 was used as the 
detecting agent (A1).  Neither TSP-Ab9 nor TSP-Ab4 detected any TSP-positivity on red 
cells that were not pre-treated with soluble TSP (A3 and A4).    
Identification of Adhesion Molecules on Erythrocytes:   Since multiple 
adhesion molecules are involved in mediating red cell adhesion to the components of 
sub-endothelial matrix, it was necessary to identify whether the other relevant adhesion 
molecules present on ionophore-activated erythrocytes were significantly altered.  As 
depicted in Table-1, among the adhesion molecules evaluated only PS showed 
differences on the ionophore activated control erythrocytes.  We also compared 
adhesion marker profiles between high PS and low PS expressing SCD groups and 
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demonstrate that the differences in adhesion marker expression was confined only to 
PS-positivity (Table-1).  
DISCUSSION 
Previous studies from our laboratories and others have documented a role for 
PS-positive red cells in erythrocyte-endothelial adhesion with data suggesting that 
adhesion was in part due to the PS-positive erythrocyte-TSP interaction. The PS-
binding site on TSP has not been characterized to date.  In this study using a dynamic 
flow adhesion assay and artificially generated PS-positive erythrocytes, we demonstrate 
that PS-positive erythrocytes bind to both immobilized and soluble thrombospondin via 
its heparin-binding domain located at the amino-terminus of the polypeptide.  We show 
that the binding is PS specific and requires the presence of both divalent cations Ca2+ 
and Mg2+.  Significant binding to TSP of erythrocytes from patients with SCD, who 
demonstrated high levels of percent PS-positive red cells, also occurred at the heparin-
binding domain.  In addition, both heparin and its low-molecular weight derivative 
enoxaparin inhibit this interaction.  
TSP is a homotrimeric 450-kDa protein, and as shown in Figure-1, each TSP 
subunit contains five distinct cell-binding domains, which interact with select protein(s), 
adhesion marker(s) or receptor(s).9-13  The heparin-binding domain which is located at 
the amino-terminus of the polypeptide interacts with heparin, heparansulfate 
proteoglycans, sulfatides, and β1-integrins.10-12  The WSPWS sequence, present within 
the type-I repeats, also interacts with heparansulfate proteoglycans.10,11  The CSVTCG 
motif that occurs twice within the type-I repeats binds to sulfatides, and CD36.10,11  The 
integrin-binding motif, RGDS, found in the last type-III repeat interacts with the 
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fibrinogen receptor αIIbβ3, and the vitronectin receptor αVβ3.10,11,13  The RFYVVM 
sequence located at the carboxy-terminal of the polypeptide binds to CD47.10,11  While 
TSP can interact with a variety of cells via multiple cell-binding domains, the PS binding 
site has not been identified to date.  PS-mediated cell binding may have potential 
implications not only in tethering of PS expressing apoptotic cells to phagocytes, but 
also in red cell-endothelial adhesion.  Our interest in characterization of PS-binding site 
on TSP is due to previously documented work including the findings from this laboratory 
demonstrating that the PS is involved in erythrocyte-endothelial adhesion4.  Since 
heparin inhibits adhesion of sickle red cells to TSP,18,30,31 we hypothesized that PS-
positive erythrocytes may bind to the heparin-binding domain on TSP.  Using artificially 
generated PS-positive control erythrocytes, we demonstrate that PS-positive red cells 
bind to immobilized TSP via its heparin-binding domain.  Our conclusion is based on the 
findings that heparin, the anti-TSP antibody recognizing the heparin-binding domain, 
and the specific TSP peptides containing the heparin-binding motif KKTRG inhibited 
PS-mediated erythrocyte adhesion to TSP (Figures 3B-C, 4A, and 5A).  Anti-TSP 
antibodies that recognize the collagen- or the CD47-binding domain, or the TSP peptide 
lacking the heparin-binding motif did not affect the binding process (Figures 4A, and 
5A).  Additional findings, demonstrating that immobilized TSP peptides containing the 
KKTRG motif supported PS-mediated erythrocyte adhesion, confirmed that PS 
interacted with TSP’s heparin-binding domain (Figure-5B).  Pathophysiologic relevance 
of this work was documented in SCD patients, since HbSS erythrocyte binding to 
immobilized TSP matrix was also significantly inhibited by the anti-TSP antibody 
recognizing the heparin-binding domain (Figure-4B).  Magnitude of the inhibitory effects 
produced by the latter anti-TSP antibody with sickle erythrocytes (a mean inhibition of 
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38%) was, however, smaller compared to that noted with artificially generated PS-
positive erythrocytes (a mean inhibition of ~80%), which could be due to the differences 
in adhesion markers expressed on these cells as shown in Table-1.  In contrast to sickle 
erythrocytes which express multiple cell adhesion markers28,32-38 with capabilities of 
interacting with multiple cell-binding domains on TSP,9-13 PS is the sole functional 
adhesion marker present on the ionophore-activated red cell and its interaction with 
TSP may, therefore, be limited to TSP’s heparin-binding domain.  Pre-treatment of 
immobilized TSP with an antibody against the heparin-binding domain may, therefore, 
produce greater inhibition with the ionophore-activated control erythrocytes.   
Besides PS, other relevant adhesion markers expressed on pathologic 
erythrocytes that are involved in red cell adhesion to endothelial cells and the sub-
endothelial matrix components include CD36,32,33 VLA4,33,34 CD47,35,36 BCAM/LU37,38 
and sulfatides.28  To exclude an ancillary role for these latter adhesion molecules in PS-
TSP adhesion, we first elected to use un-activated and ionophore-activated control 
HbAA erythrocytes where, as shown in Table-1, ionophore treatment did not alter the 
expression of other adhesion molecules except causing PS-positivity i.e. the ideal 
condition for our proposed experiments related to PS-TSP adhesion.  In addition, 
pretreatment of TSP with an antibody that recognizes the CD47-binding domain on TSP 
had no effect on ionophore-activated erythrocyte adhesion (Figure-4A).  Further, while it 
is not known whether erythrocyte activation with A23187 perturbs membrane sulfatide 
composition, pretreatment of immobilized TSP with bovine brain sulfatide had no effect 
on A23187-treated red cell binding (Figure-3C).  These results demonstrate that the 
erythrocyte adhesion molecules including CD47, BCAM/LU and sulfatides do not 
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appear to be involved in mediating ionophore-activated erythrocyte binding to the 
heparin-binding domain on TSP.  
 Protein conformational changes may affect the cell-binding characteristics of 
TSP.39  For example, studies have demonstrated that chelation of Ca2+ unfolds the 
globular cell-binding domain of TSP, destabilizes disulfide bonds and results in 
extensive thiol-disulfide exchange leading to altered cell-binding characteristics.40-42  We 
therefore evaluated the effects of divalent cations including Ca2+ and Mg2+, and found a 
12-fold increase in PS-mediated erythrocyte binding to TSP in the presence of Ca2+, 
although this effect also required the presence of Mg2+.  Additionally, both Ca2+ and 
Mg2+, by decreasing molecular motion of the PS head groups and narrowing the 
distance between the neighboring PS head groups,43 may maximize binding of PS-
positive erythrocytes to TSP.  Protein conformation of immobilized matrix TSP also 
appears to be different from that of soluble TSP as previously documented by 
differential adhesion of sickle erythrocytes to soluble verses immobilized matrix 
TSP.28,32,44  While soluble TSP-mediated sickle red cell adhesion to cultured endothelial 
cells was blocked by both OKM-5 (a murine monoclonal antibody against CD36) and by 
a TSP peptide containing the CD36-binding motif CSVTCG,32 these blocking agents 
had no effect on sickle erythrocyte adhesion to immobilized matrix TSP.28,44  In light of 
these documented differential effects of blocking agents on sickle erythrocyte adhesion 
to TSP, we elected to also evaluate soluble TSP interactions with PS-positive cells.  We 
found that soluble TSP, like immobilized TSP, appears to interact with PS-positive 
erythrocytes via its heparin-binding domain.  We demonstrate that erythrocytes acquire 
TSP-positivity following incubation of PS-positive red cells with soluble TSP.  No TSP 
positivity was found on the surface of erythrocytes that were incubated in the absence 
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of TSP, or PS-negative red cells incubated with soluble TSP (Figure-6).  In addition, 
TSP positivity was noted when an antibody recognizing the collagen-binding domain, 
but not an antibody recognizing the heparin-binding domain, was used as the detecting 
agent, likely due to preoccupancy of the heparin-binding domain, the binding site for 
anti-TSP-Ab9, on the TSP molecule by PS-positive erythrocytes.  Since TSP is one of 
the components of the sub-endothelial matrix, in its immobilized form it facilitates 
adhesion of PS-positive red cells to sub-endothelium.  In its soluble form TSP 
transforms a PS-positive red cell into a TSP-positive red cell which can interact not only 
with multiple adhesion receptors including CD36, CD47, α4β1, αvβ3 and αIIbβ3, but 
may also, potentially, play a role in the formation of hetero-cellular aggregates by 
facilitating adhesive interactions with other circulating cellular elements of blood 
including platelets and monocytes, as well as vascular endothelial cells.  In this context 
it is interesting to note that previous studies in patients with SCD documented the 
presence of platelet-erythrocyte and neutrophil-erythrocyte aggreagates.45-47   
Previous studies have evaluated the effects of several anionic polysaccharides 
including heparin, CSA and HDS on sickle erythrocyte adhesion to both immobilized 
matrix and soluble TSP and found differential inhibitory effects,18,28,31,44 in contrast to 
inhibition of a similar magnitude noted in this study with artificially generated PS-positive 
erythrocytes.  These differences could be due to polysaccharides’ ability to recognize 
multiple GAG binding domains on TSP, as previously documented with CSA, which in 
addition to its interaction with the heparin binding domain, can also bind to regions 
within the type-I repeats and also to regions in the carboxy-terminal cell binding 
domain.48  Heparin has been used clinically as an anti-coagulant and anti-thrombotic 
agent.49  Major clinical concerns of prolonged heparin therapy, however, include 
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heparin-induced thrombocytopenia, and abnormal bleeding.  To overcome these 
adverse clinical effects of unfractionated heparin, several low molecular weight heparin 
derivatives have been developed, which have numerous advantages over 
unfractionated preparations including clinical safety and efficacy.50  In the present study 
we tested the effects on adhesion of heparin and enoxaparin, a low molecular weight 
heparin derivative, and demonstrate that both these polysaccharides inhibited PS-
mediated erythrocyte adhesion to immobilized TSP not only at pharmacologic 
concentrations (5 to 50 U/ml) but also at levels (0.5 U/ml) achievable clinically in 
patients.49,51  Other investigators have demonstrated that heparin can inhibit soluble 
TSP-,18,31 and P-selectin-30 mediated sickle erythrocyte adhesion to cultured human 
endothelial cells.  In addition, a previous study has suggested that prophylactic heparin 
therapy reduced the frequency of vaso-occlusive pain in patients with SCD.52  Our 
results taken together with those previously published demonstrate that heparin can 
modulate multiple red cell adhesion pathways in patients with SCD and suggests that 
heparin and its low molecular weight derivatives may be useful as potential therapeutic 
agents targeting the enhanced pro-adhesive state in this patient group.   
In summary, we have demonstrated that PS-positive erythrocytes bind to both 
immobilized and soluble thrombospondin via its heparin-binding domain located at the 
amino-terminus of the polypeptide.  We have shown that soluble TSP by binding to PS-
positive red cells can potentially generate a sub-population of red cells which are TSP-
positive with potentially enhanced pro-adhesive capabilities.  In addition, we have 
demonstrated that heparin and its low molecular weight derivative enoxaparin inhibit 
PS-mediated erythrocyte-TSP interaction.  The therapeutic potential of these 
observations are germane not only to sickle cell disease pathogenesis, but to other 
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disorders in which a proadhesive propensity due to cellular PS-thrombospondin 
interactions exacerbates disease pathophysiology.   
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LEGENDS to FIGURES 1 through 6 
 
Figure-1:   Structure of thrombospondin subunit. 
Schematic diagram modified from Gupta et al18 depicting the different structural 
domains and cell binding regions of the TSP subunit relevant to erythrocyte adhesion to 
endothelial cells and/or to the components of sub-endothelial matrix.  Each subunit of 
the TSP molecule contains several structural domains including the N-terminal, the C-
terminal and the pro-collagen homology domains, the oligomerization sequence, and 
three type 1 properidine repeats, three type 2 EGF-like repeats and seven type 3 
calcium binding repeats.  Erythrocyte-related cell surface receptors, proteins and 
adhesion markers that have been reported to interact with various regions of TSP 
molecule are shown in red.  Anti-TSP antibodies used in this study are shown in blue 
boxes above their respective TSP interacting domains. HSPGs: heparan sulfate 
proteoglycans.  In other BBXB sequences, B is a basic amino acid and X is any amino 
acid.    
Figure 2:  Adhesion of PS-positive Erythrocytes to Immobilized Thrombospondin.  
Panel A:  PS-positive erythrocytes bind to immobilized TSP matrix in a 
concentration-dependent manner. Adhesion of erythrocytes (2X108 cells per ml 
containing 0.5 to 17% PS-positive red cells) was evaluated using a TSP matrix 
(containing 50 ng of protein per square cm) as described in methods.   
Panel B:  Immobilized TSP supports erythrocyte binding in a concentration-
dependent Manner.  Red cells (2X108 cells per ml containing 12% PS positivity) were 
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evaluated in adhesion assays employing matrices containing 25 to 200 ng of protein per 
square cm. 
Figure-3:  Modulation of PS-mediated erythrocyte binding to immobilized TSP by 
annexin V, heparin, enoxaparin, HDS, CSA, and sulfatide.  
Panel A:  Annexin V reduces PS binding sites on the red cell surface (measured 
as mean cell fluorescence or MCF) and inhibits erythrocyte adhesion to immobilized 
TSP.  Erythrocytes (1X108 cells/ml containing 12% PS-positive cells) were pre-
incubated in the presence or absence of the indicated concentrations of annexin-V, and 
then assessed for their adhesive potential (diamonds) and residual surface PS (circles) 
as described.  Values presented are the means ± SD from 3 (annexin V between 3 and 
28 µg/ml) to 5 (annexin V at 57 µg/ml) different experiments. The number of PS-positive 
erythrocytes adhered in the absence of annexin V was 639 ± 147 cells/mm2.  *Changes 
noted with annexin V at 57 µg/ml were statistically significant at P<0.05. 
Panel B: Heparin and enoxaparin inhibit PS-mediated erythrocyte binding to 
immobilized thrombospondin in a concentration-dependent manner.  Red cells (2X108 
cells/ml containing 12% PS-positive cells) were pre-treated with the indicated 
concentrations (0.1 to 50 U/ml) of heparin (circles) or Lovenox (squares), and then 
assessed for their adhesive potential using a TSP matrix containing 50 ng protein per 
cm2 as described in methods.  Values presented are the means ± SD from 5 (Lovenox), 
or 9 (heparin) different experiments.  *Inhibitory effects noted with heparin (between 0.5 
and 50 U/ml) and Lovenox (between 0.5 and 50 U/ml) were statistically significant at 
P<0.05.   The number of PS-positive erythrocytes adhered in the absence of modulators 
were 632 ± 241 cells/mm2.  
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 Panel C: Effects of glycosaminoglycans (GAGs), and sulfatide on PS-mediated 
erythrocyte binding to immobilized thrombospondin.  Effects of high molecular weight 
dextran sulfate, MW 500,000 (HDS, 200 µg/ml), chondroitin sulfate A (CSA, 200 µg/ml), 
and bovine brain sulfatide (200 µg/ml) on PS-mediated RBC-TSP binding were 
evaluated using erythrocytes (2X108 cells/ml) containing 12% PS and TSP matrix at 50 
ng/cm2.  Values presented are the means ± SD from 6 different experiments.  Heparin 
(200 µg/ml, equivalent to 50 units/ml) tested in parallel with other GAGs is shown for 
paired comparison with HDS and CSA. *Red cell adhesion in the presence of heparin, 
HDS and CSA were different from the respective paired controls as assessed by the 
paired student’s t-test at P<0.01.   
Figure-4: Effects of anti-TSP antibodies on PS-mediated erythrocyte binding to 
immobilized TSP.   
Panel A: Anti-TSP antibody that recognizes TSP’s heparin-binding domain (α-
TSP-Ab9) inhibits PS-mediated erythrocyte binding to immobilized thrombospondin. 
Antibody-treated TSP matrices were tested for their adhesive potential using 
erythrocytes (2X108 cells/ml) containing 12% PS-positive cells.  Values presented are 
the means ± SD from 7 different experiments.  *Inhibition noted with TSP-Ab9 was 
statistically significant at P<0.05 when compared to either TSP-Ab3, TSP-Ab4, or the 
isotype-matched negative immunoglobulin control.  Both anti-TSP-Ab4 and the negative 
immunoglobulin control demonstrated minimal inhibitory effects on red cell binding 
which were not statistically significant.  The antibodies, TSP-Ab3 and TSP-Ab4 
recognize the C-terminal CD47- and the collagen- binding domain on TSP, respectively.   
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Panel B: Effects of anti-TSP antibody Ab9 on binding of sickle erythrocytes to 
immobilized thrombospondin:  TSP matrices were pre-incubated in the presence or 
absence of anti-TSP-Ab9 (an antibody that recognizes the heparin binding domain on 
TSP), or an equivalent amount of an isotype-matched negative immunoglobulin control 
for 30 minutes prior to their use in flow adhesion.  Pre-treated matrices were then tested 
for their binding potential using red cells from patients with sickle cell disease, HbSS 
genotype (2X108 cells per ml).  The gray and black bars represent adhesion of HbSS 
erythrocytes with low (1.1 ± 0.5% positivity) and high (6.6 ± 1.7% positivity) PS 
positivity, respectively.  Results presented are the means ± SD from 5 (low PS) or 7 
(high PS) experiments.  *P<0.05 compared to the respective vehicle or the isotype 
control.    
Figure-5: Effects of TSP peptides on PS-mediated erythrocyte binding to 
immobilized TSP and adhesion of PS-positive red cells to immobilized peptides. 
Panel A: Peptides from TSP’s heparin binding domain containing the heparin 
binding motif KKTRG inhibit PS-mediated erythrocyte binding to immobilized 
thrombospondin.  Peptide (50µM)-treated erythrocytes (2X108 cells/ml containing 12% 
PS-positive cells) were tested for their adhesive potential to immobilized TSP.  Both 
peptides -1 and -2 contained the heparin binding motif of TSP molecule (positive 
peptides) with the following amino acid sequences, peptide-1: KKTRGTLLALERKDHS 
(residues 80-95 of TSP subunit, the binding motif is shown in bold), peptide-2: 
VDAVRTEKGFLLLASRQMKKTRGT (residues 61-85 of TSP molecule).  Peptide-3, 
TLLALERKDHS (residues 85-95 of TSP molecule, a negative peptide) lacked the 
heparin binding motif.  Values presented are the means ± SD from 7 different 
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experiments.  *Erythrocyte adhesion in the presence of positive TSP peptides was 
significantly different from the respective controls as assessed by the paired student’s t-
test at P<0.001.  
Panel B:  Immobilized peptides from TSP’s heparin binding domain containing 
the binding motif KKTRG support PS-mediated erythrocyte binding.  Thrombospondin 
peptides were immobilized on glass slides using 0.5M bicarbonate buffer, pH 9.6 at 10 
µg/cm2.  Adhesion of erythrocytes (2X108 cells/ml containing 12% PS-positive cells) to 
immobilized TSP peptides was evaluated as described in methods.  Values presented 
are the means ± SD from 3 different experiments.  Erythrocyte binding to positive TSP 
peptides (peptides -1 and -2) was significantly different from the respective vehicle 
controls as assessed by the paired student’s t-test at P<0.02. There was no difference 
in red cell binding between the vehicle control and the negative peptide.   
Figure-6:  Soluble thrombospondin binds to PS-positive erythrocytes and 
transforms PS-positive red cells to TSP-positive erythrocytes: 
Panel A:  Treatment of PS-positive erythrocytes with soluble TSP transforms PS-
positive red cells into TSP-positive erythrocytes:  Erythrocytes (1X108 cells/ml 
containing 12% PS-positive cells) were pre-incubated in the presence or absence of the 
indicated concentrations of soluble TSP, washed and then assayed for TSP-positivity 
using TSP antibodies: TSP-Ab4 (cross-hatched bars) and TSP-Ab9 (gray-hatched 
bars).  TSP-positivity measured in parallel experiments with PS-negative control red 
cells using TSP-Ab4 is also shown (black solid bars) for comparison.  Values presented 
are the means ± SD from 4 different experiments.     
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Panel B: Histogram profiles of TSP-positive erythrocytes:  Erythrocytes (1X108 
cells/ml containing 12% PS-positive cells) were pre-incubated in the presence (panels 
A1 and A2) or absence (panels A3 and A4) of soluble TSP (10 µg/ml) and then assayed 
for TSP positivity using anti-TSP-Ab4 (panels A2 and A4) or anti-TSP-Ab9 (panels A1 
and A3).   Histogram profiles of TC fluorescence from cells labeled with anti-TSP 
antibodies (gray histograms) and isotype-matched negative immunoglobulin control 
(solid black lines) are shown in each panel.  The marker M1 is the positive histogram 
region defined using red cells labeled with the isotype-matched negative 
immunoglobulin control.  Percent marker-positive cell, shown in each panel, is the 
difference in M1 between the cells labeled with anti-TSP and the isotype-matched 
negative immunoglobulin control.  Results presented are from a representative 
experiment repeated four times with similar results.  Note that the TSP-positivity was 
observed only with anti-TSP-Ab4 (an antibody that recognizes the collagen-binding 
domain on TSP).  TSP positivity was almost undetectable when anti-TSP-Ab9 (an 
antibody that recognizes the heparin-binding domain on TSP) was used as the 
detecting agent, likely due to preoccupancy of the heparin binding domain on the TSP 
molecule by PS-positive erythrocytes.  The TC-conjugated second antibody used in 
these experiments was labeled with PE-Cy5.  This fluorochrome is excitated at 488 nm 
and emission detected at 667 nm.  Its red fluorescence is detected in the FL3 channel 
on a FACScan flow cytometer.     
